Overview

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of Diclofenac Sodium Topical Gel (DSTG) on injection site reaction following self-administer glatiramer acetate in people with Multiple Sclerosis.
Phase:
Phase 4
Details
Lead Sponsor:
Brown, Theodore R., M.D., MPH
Collaborator:
Teva Neuroscience, Inc.
Treatments:
Diclofenac
Glatiramer Acetate